컨텐츠 바로가기

About iNtRON

㈜인트론바이오는 바이오신약 ‘R&BD 방향’을
‘사람대상’, ‘질병치료제’, ‘First-in-Class (MOA based)’로
설정하고 있으며, 이러한 방향을 지켜나가는 한,
“글로벌 R&D 그룹”으로서, 폭넓고, 자유롭게,
그리고 열정적으로 사업을 영위해 나갈 것입니다!
MORE

논문발표 현황

  • Pharmacokinetics and Tolerance of the Phage Endolysin-Based Candidate Drug SAL200 after a Single Intravenous Administration among Healthy Volunteers. Antimicrob Agents Chemother. 2017 May 24;61(6).

  • "Evaluating the effectiveness of Streptococcus parauberis bacteriophage Str-PAP-1 as an environmentally friendly alternative to antibiotics for aquaculture" Aquaculture., 468(Part 1):464-470, 2017

  • “Pharmacokinetics of the phage endolysin-based candidate drug SAL200 in monkeys and its appropriate intravenous dosing period” Clin. Exp. Pharmacol. Physiol. 43(10): 1013-1016, 2016

  • “The herbal-derived honokiol and magnolol enhances immune response to infection with methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant S. aureus (MRSA)” Appl. Microbiol. Biotechnol. 99(10): 4387-4396, 2015

  • “이유자돈에서 Salmonella Typhimurium 감염에 대한 박테리오파지의 방어 효능” 한국가축위생학회지 37(1), 35-43, 2014

  • “Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient” Antimicrob. Agents Chemother. 58(4), 2084-2088, 2014

  • “Effect of gene amplifications in porphyrin pathway on heme biosynthesis in a recombinant Escherichia coli” J. Microbiol. Biotechnol. 23(5), 668-673, 2013

  • “Antibacterial properties of a pre-formulated recombinant phage endolysin, SAL-1” Int. J. Antimicrob. Agents 41(2), 156-161, 2013

  • “Mannose-poly(ethylene glycol)-linked SPION targeted to antigen presenting cells for magnetic resonance imaging on lymph node” Carbohyd. Polym. 92(2), 1586-1595, 2013

  • “Porphyrin Derivatives from a Recombinant Escherichia coli Grown on Chemically Defined Medium” J. Microbiol. Biotechnol. 22(12), 1653-1658, 2012